Neoadjuvant therapy in non-small cell lung cancer

被引：4
|
作者：
Grant, Christopher [1 ]
Hagopian, Garo [1 ]
Nagasaka, Misako [1 ,2 ,3 ,4 ]
机构：
[1] Univ Calif Irvine, Sch Med, Dept Med, Orange, CA USA
[2] Univ Calif Irvine, Sch Med, Dept Med, Div Hematol & Oncol, Orange, CA USA
[3] St Marianna Univ, Sch Med, Dept Internal Med, Div Neurol, Kawasaki 2168511, Japan
[4] Univ Calif Irvine, UC Irvine Hlth, Med Ctr, Dept Med,Div Hematol & Oncol, 200 S Manchester Ave, Room 423, Orange, CA 92868 USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 190卷
关键词：
Perioperative chemotherapy; Perioperative immunotherapy; Neoadjuvant targeted therapy; CheckMate; 816; AEGEAN; PHASE-III; INDUCTION CHEMOTHERAPY; PLUS CHEMOTHERAPY; OPEN-LABEL; SURGERY; TRIAL; PEMBROLIZUMAB; OSIMERTINIB;
D O I：
10.1016/j.critrevonc.2023.104080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and chemotherapy was FDA approved for the treatment of resectable NSCLC. There are several ongoing trials evaluating other neoadjuvant combinations of chemotherapy and immunotherapy as well as targeted therapies towards driver mutations. Here, we review previous clinical trials and discuss current ongoing trials' potential benefits and challenges.
引用
收藏
页数：8
相关论文
共 50 条
  • [21] Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
    Grant, Christopher
    Nagasaka, Misako
    [J]. CANCER TREATMENT REVIEWS, 2024, 126
  • [22] Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer
    Pisters, KMW
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 23 - 28
  • [23] Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer
    Watanabe, Shun-ichi
    Nakagawa, Kazuo
    Suzuki, Kenji
    Takamochi, Kazuya
    Ito, Hiroyuki
    Okami, Jiro
    Aokage, Keiju
    Saji, Hisashi
    Yoshioka, Hiroshige
    Zenke, Yoshitaka
    Aoki, Tadashi
    Tsutani, Yasuhiro
    Okada, Morihito
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (12) : 1112 - 1118
  • [24] Cellular changes in non-small cell lung cancer after neoadjuvant therapy
    Junker, K
    Müller, KM
    Abker, S
    Bosse, U
    Klinke, F
    Thomas, M
    [J]. PATHOLOGE, 2004, 25 (03): : 193 - 201
  • [25] Repeat mediastinoscopy after neoadjuvant therapy for non-small cell lung cancer
    Maas, KW
    Schramel, FMNH
    [J]. LUNG CANCER, 2003, 39 (03) : 347 - 347
  • [26] Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
    Kalvapudi, Sukumar
    Vedire, Yeshwanth
    Yendamuri, Sai
    Barbi, Joseph
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [27] Neoadjuvant Therapy with Immune Checkpoint Inhibitors in operable non-small cell Lung Cancer
    Hekmat, Khosro
    Bruns, Christiane J.
    [J]. CHIRURG, 2021, 92 (08): : 735 - 735
  • [28] Neoadjuvant therapy and surgical resection for locally advanced non-small cell lung cancer
    Meko, J
    Rusch, VW
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (04) : 324 - 332
  • [29] Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
    Conroy, Michael R.
    Dennehy, Colum
    Forde, Patrick M.
    [J]. LUNG CANCER, 2023, 183
  • [30] Grading of tumor regression in non-small cell lung cancer after neoadjuvant therapy
    Junker, K
    Thomas, M
    Schulmann, K
    Klinke, V
    Bosse, U
    Muller, KM
    [J]. PATHOLOGE, 1997, 18 (02): : 131 - 140
12345